📣 VC round data is live. Check it out!

10x Genomics Valuation Multiples

Discover revenue and EBITDA valuation multiples for 10x Genomics and similar public comparables like Insight Lifetech, BGI Genomics, GRAIL, Bloomage BioTechnology and more.

10x Genomics Overview

About 10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).


Founded

2012

HQ

United States

Employees

1.2K

Financials (LTM)

Revenue: $632M
EBITDA: ($49M)

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

10x Genomics Financials

10x Genomics reported last 12-month revenue of $632M and negative EBITDA of ($49M).

In the same LTM period, 10x Genomics generated $435M in gross profit, ($49M) in EBITDA losses, and had net loss of ($66M).

Revenue (LTM)


10x Genomics P&L

In the most recent fiscal year, 10x Genomics reported revenue of $643M and EBITDA of $4M.

10x Genomics is unprofitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 1%, and net margin of (7%).

See analyst estimates for 10x Genomics
LTMLast FY202320242025202620272028
Revenue$632M$643M$619M$611M$643M
Gross Profit$435M$444M$409M$414M$444M
Gross Margin69%69%66%68%69%
EBITDA($49M)$4M($205M)($134M)$4M
EBITDA Margin(8%)1%(33%)(22%)1%
EBIT Margin(13%)(9%)(33%)(32%)(17%)
Net Profit($66M)($44M)($255M)($183M)($44M)
Net Margin(10%)(7%)(41%)(30%)(7%)

Financial data powered by Morningstar, Inc.

10x Genomics Stock Performance

10x Genomics has current market cap of $3B, and enterprise value of $2B.

Market Cap Evolution


10x Genomics' stock price is $21.59.

10x Genomics share price decreased by 2.1% in the last 30 days, and increased by 126.6% in the last year.

10x Genomics has an EPS (earnings per share) of $-0.34.

See more trading valuation data for 10x Genomics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$3B0.0%-2.1%-6.3%126.6%$-0.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

10x Genomics Valuation Multiples

10x Genomics trades at 3.7x EV/Revenue multiple, and (47.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for 10x Genomics

EV / Revenue (LTM)


10x Genomics Financial Valuation Multiples

As of May 10, 2026, 10x Genomics has market cap of $3B and EV of $2B.

10x Genomics has a P/E ratio of (42.2x).

LTMLast FY202320242025202620272028
EV/Revenue3.7x3.6x3.8x3.8x3.6x
EV/EBITDA(47.2x)n/m(11.3x)(17.4x)n/m
EV/EBIT(28.5x)(39.1x)(11.4x)(12.0x)(21.0x)
EV/Gross Profit5.4x5.2x5.7x5.6x5.2x
P/E(42.2x)(64.0x)(10.9x)(15.3x)(64.0x)
EV/FCFn/m17.9x(36.0x)n/m17.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified 10x Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

10x Genomics Margins & Growth Rates

10x Genomics decreased revenue by 5% and EBITDA by 2448% in the last fiscal year.

In the most recent fiscal year, 10x Genomics reported gross margin of 69%, EBITDA margin of 1%, and net margin of (7%).

See estimated margins and future growth rates for 10x Genomics

10x Genomics Margins

Last FY202420252026202720282029
Gross Margin69%68%69%68%
EBITDA Margin1%(22%)1%(15%)
EBIT Margin(9%)(32%)(17%)(20%)
Net Margin(7%)(30%)(7%)(17%)
FCF Margin20%(1%)20%1%

10x Genomics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(5%)(1%)5%(5%)
Gross Profit Growth(7%)1%7%(7%)
EBITDA Growth(2448%)(35%)(103%)(2448%)
EBIT Growth104%(5%)(43%)10%
Net Profit Growth145%(28%)(76%)145%
FCF Growth(93%)(90%)(2034%)(93%)

Data powered by FactSet, Inc. and Morningstar, Inc.

10x Genomics Operational KPIs

10x Genomics' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.

10x Genomics' Rule of 40 is (20%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

10x Genomics' Rule of X is (26%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for 10x Genomics
LTMLast FY202320242025202620272028
Rule of 40(8%)(20%)
Bessemer Rule of X(8%)(26%)
Revenue per Employee$0.5M
Opex per Employee$0.5M
R&D Expenses to Revenue36%37%44%43%37%
Opex to Revenue86%99%100%86%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

10x Genomics Competitors

10x Genomics competitors include Insight Lifetech, BGI Genomics, GRAIL, Bloomage BioTechnology, Veracyte, Adaptive Biotech, Genus, Twist Bioscience, Syngene and Generate Biomedicines.

Most 10x Genomics public comparables operate across Life Sciences Tools, Diagnostics & Genomics, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Insight Lifetech32.7x147.3x
BGI Genomics4.1x4.1x52.0x48.2x
GRAIL12.7x11.8x(5.0x)(5.2x)
Bloomage BioTechnology4.6x4.5x26.7x25.9x
Veracyte5.5x5.2x19.8x19.3x
Adaptive Biotech7.5x7.4x164.9x258.5x
Genus2.6x2.6x14.7x13.3x
Twist Bioscience9.2x8.3x(73.8x)(89.9x)

This data is available for Pro users. Sign up to see all 10x Genomics competitors and their valuation data.

Start Free Trial

10x Genomics Funding History

Before going public, 10x Genomics raised $238M in total equity funding, across 5 rounds.

Last private valuation of 10x Genomics was $1B, after raising $35M in January 2019 from Fidelity, Meritech Capital Partners, and Wells Fargo.


10x Genomics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-19Series DFidelity; Meritech Capital Partners; Wells Fargo$35M$1B10x Genomics is a medical research technology company that develops and produces instruments and software for use in biomedical research. The company's platforms, including Chromium and Visium, enable analysis of biological systems at unprecedented resolution and scale, with applications in cancer research, immunology, and genomic discovery. The company was founded in 2012 and had raised approximately $243 million across multiple rounds by early 2019. In January 2019, 10x Genomics closed its Series D financing with a $35 million second tranche led by Meritech Capital Partners, with participation from Fidelity and Wells Fargo Strategic Capital. The Series D valued the company at $1.28 billion post-money. In the first half of 2019, the company generated revenue of more than $109 million on an annualized basis, more than doubling year-over-year revenue, while reducing net losses from $21.6 million to $14.5 million over the same period. The company demonstrated strong product-market fit with a twenty-fold revenue increase from 2015 to 2017, expanded manufacturing and R&D operations in California, and opened offices in Singapore and Shanghai to serve growing Asian markets. Shortly after the Series D, 10x Genomics launched new products including Chromium Single Cell ATAC Solution and Feature Barcoding technology to enable multi-omics analysis. The company proceeded to complete a successful IPO on September 12, 2019, raising approximately $390 million at an implied valuation of $3.66 billion.
Apr-18Series DFidelity; Meritech Capital Partners; Paladin Capital Group; SoftBank Group; Wells Fargo Strategic Capital$50M$1B10x Genomics develops instruments, consumables, and software for single-cell and spatial genomics analysis, accelerating genomic discovery through innovations like the Chromium instrument with over 600 global installs by 2018. In April 2018, the company announced a $125 million funding package including a $50 million Series D equity round led by Meritech Capital Partners, with participation from Fidelity, Paladin Capital Group, SoftBank Vision Fund (as SoftBank Group), and new investor Wells Fargo Strategic Capital, complemented by a $75 million debt facility from Silicon Valley Bank, bringing total financing to over $240 million. The company reported achieving over $100 million in cumulative revenue since mid-2015 product introduction, with revenues growing over 150% year-over-year as shared at the JPMorgan Healthcare conference earlier in 2018. In its first 30 months, 10x launched 25 products across instruments, reagents, and software, establishing leadership in single-cell analysis. Proceeds supported innovation, including 2018 product launches like single-cell DNA sequencing for oncology, multi-omic protein and gene expression measurements, and epigenomic analysis. Funds also expanded global commercial operations with new offices in Leiden, Netherlands, and Shanghai, China, internal manufacturing, and hiring up to 200 staff. A $35 million Series D extension in April 2019, again led by Meritech with Fidelity and Wells Fargo, resulted in a $1.28 billion valuation.
Feb-16Series CFidelity; Foresite Capital; Paladin Capital Group; SoftBank Group; Venrock$75M10x Genomics, a biotechnology company focused on developing technologies to improve and broaden genomic applications, completed a $55 million Series C financing on March 17, 2016, led by Fidelity Management & Research Company, with participation from new investors SoftBank and JS Capital Management LLC, alongside existing backers Venrock, Foresite Capital, and Paladin Capital Group. The funds were intended to accelerate marketing and sales efforts for its GemCode and Chromium products, which revolutionize genome sequencing by providing linked-reads for haplotyping, structural variation, and de novo assembly, while integrating with existing lab infrastructure. The company was commercializing a platform that complements current sequencers to access previously unavailable genetic information through whole genome sequencing, deep exome analysis, and single cell gene expression. The products were positioned to transform commercial reach globally via key collaborations and partnerships, meeting demand for innovative genomic variation analysis tools. The company continued raising capital, culminating in a $390 million IPO in September 2019 at an implied valuation of around $3.66 billion to $4 billion, after total private funding of approximately $243 million to $277 million across multiple rounds. Post-IPO, 10x Genomics reported $109 million in revenue for the first half of 2019 but incurred a $14.5 million net loss.
Dec-14Series BForesite Capital; Paladin Capital Group; Venrock$56M10x Genomics is a biotechnology company founded in 2012 that provides an innovative genomics platform for life sciences research, including applications in oncology, immunology, and neuroscience. The platform uses microfluidics, chemistry, and bioinformatics to upgrade the capabilities of existing short-read sequencers, enabling researchers to identify structural variants, haplotypes, and long-range genomic information while leveraging existing sequencing workflows. In December 2014, the company closed a Series B funding round of $55.5 million led by Foresite Capital, with participation from Series A lead Venrock, Paladin Capital Group, and funds managed by Morgan Stanley Investment Management, bringing total financing to over $80 million at that time. The company had previously completed a Series A round of $22.4 million in November 2013. 10x Genomics went on to achieve significant growth, completing a Series D extension of $35 million in January 2019 led by Meritech Capital, and ultimately completing an initial public offering on September 12, 2019 on NASDAQ under ticker TXG at an implied valuation of $3.66 billion.
Nov-13Series AVenrock$22MLater funding included a $55.5 million Series B in 2015 led by Foresite Capital Management with participation from Venrock (Series A lead), bringing total raised to over $80 million at that point. The company develops an innovative genomics platform using microfluidics, chemistry, and bioinformatics to enhance short-read sequencers for detecting structural variants, haplotypes, and long-range genomic information. 10x Genomics' products enable single-cell gene expression analysis and are used by top research institutions and pharmaceutical companies. The company went public in 2019 with strong IPO performance, reaching a nearly $5 billion market cap, and made acquisitions like Epinomics and Spatial Transcriptomics to expand into epigenetics and spatial transcriptomics.

10x Genomics M&A Activity

10x Genomics has acquired 7 companies to date.

Last acquisition by 10x Genomics was on August 7th 2025. 10x Genomics acquired Scale Biosciences for $30M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by 10x Genomics

Scale Biosciences
Tetramer Shop
ReadCoor
CARTANA
Description
Scale Biosciences is a life sciences company developing single-cell profiling technologies for genomics, transcriptomics, and multi-omics research. The firm's scalable platforms enable high-throughput analysis of thousands of cells per sample, supporting drug discovery and precision medicine applications. Scale Biosciences serves academic labs, biopharma companies, and research institutes with automated workflows and cloud-based data processing.
Tetramer Shop is a supplier of MHC tetramers for detecting and monitoring antigen-specific T cells in immunotherapy research. Martinsried-headquartered near Munich, it offers fluorescently labeled tetramers for HLA-A2, HLA-B7, and other alleles used in flow cytometry assays. Products support T cell epitope mapping in vaccine development and cancer immunology studies.
ReadCoor is a Seattle-headquartered biotech firm offering the RC2 spatial multi-omics platform for tissue analysis. The technology uses Fluorescent in situ Sequencing to map RNA, DNA, proteins, and drugs at nanoscale 3D resolution across entire tissue sections. Targeted at pharma companies like Bristol Myers Squibb and researchers at Stanford, ReadCoor processes samples from tumors and organs, revealing subcellular interactions. Launched in 2022 from the Wyss Institute, its FISSEQ method scales to thousands of targets per experiment.
CARTANA is a Swedish biotechnology company specializing in In Situ Sequencing for mapping gene expression in brain tissue. Located in Stockholm, its ISS technology analyzes hundreds of genes per cell while preserving tissue morphology. The platform supports neuroscience research, biomarker discovery, and treatment validation in areas like Alzheimer's and Parkinson's. Founded in 2014, CARTANA was acquired by 10x Genomics in 2020, expanding its reach to global labs studying cellular interactions.
HQ CountryUnited StatesDenmarkUnited StatesSweden
HQ City
San Diego, CA
Copenhagen
Stockholm
Deal Date7 Aug 202525 Feb 20215 Oct 202021 Sep 2020
Valuation$30Mundisclosed$407M$35M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all 10x Genomics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About 10x Genomics

When was 10x Genomics founded?10x Genomics was founded in 2012.
Where is 10x Genomics headquartered?10x Genomics is headquartered in United States.
How many employees does 10x Genomics have?As of today, 10x Genomics has over 1K employees.
Who is the CEO of 10x Genomics?10x Genomics' CEO is Serge Saxonov.
Is 10x Genomics publicly listed?Yes, 10x Genomics is a public company listed on Nasdaq.
What is the stock symbol of 10x Genomics?10x Genomics trades under TXG ticker.
When did 10x Genomics go public?10x Genomics went public in 2019.
Who are competitors of 10x Genomics?10x Genomics main competitors include Insight Lifetech, BGI Genomics, GRAIL, Bloomage BioTechnology, Veracyte, Adaptive Biotech, Genus, Twist Bioscience, Syngene, Generate Biomedicines.
What is the current market cap of 10x Genomics?10x Genomics' current market cap is $3B.
What is the current revenue of 10x Genomics?10x Genomics' last 12 months revenue is $632M.
What is the current revenue growth of 10x Genomics?10x Genomics revenue growth (NTM/LTM) is (0%).
What is the current EV/Revenue multiple of 10x Genomics?Current revenue multiple of 10x Genomics is 3.7x.
Is 10x Genomics profitable?No, 10x Genomics is not profitable.
What is the current EBITDA of 10x Genomics?10x Genomics has negative EBITDA and is not profitable.
What is 10x Genomics' EBITDA margin?10x Genomics' last 12 months EBITDA margin is (8%).
What is the current EV/EBITDA multiple of 10x Genomics?Current EBITDA multiple of 10x Genomics is (47.2x).
What is the current FCF of 10x Genomics?10x Genomics' last 12 months FCF is ($4M).
What is 10x Genomics' FCF margin?10x Genomics' last 12 months FCF margin is (1%).
What is the current EV/FCF multiple of 10x Genomics?Current FCF multiple of 10x Genomics is (573.9x).
How many companies 10x Genomics has acquired to date?As of May 2026, 10x Genomics has acquired 6 companies.
What was the largest acquisition by 10x Genomics?$407M acquisition of ReadCoor on 5th October 2020 was the largest M&A 10x Genomics has done to date.
What companies 10x Genomics acquired?10x Genomics acquired ReadCoor, CARTANA, Scale Biosciences, EPINOMICS, Tetramer Shop, and Spatial Transcriptomics.
In how many companies 10x Genomics has invested to date?10x Genomics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to 10x Genomics

Lists including 10x Genomics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial